Seth Lederman, Tonix Pharmaceuticals CEO

Tonix cuts in­ter­im analy­ses of two tri­als, halves en­roll­ment in one

Tonix Phar­ma­ceu­ti­cals ap­pears to be strapped for cash.

Af­ter cut­ting down on its Covid-19 work ear­li­er this month in fa­vor of its late-stage fi­bromyal­gia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.